Upstate Active Clinical Trials

Study Title:

GSK Protocol BRF113928: A Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-small cell lung cancer

What is the purpose of the study?

abrafenib is a potent and selective inhibitor of BRAF kinase activity. This is a Phase II, non-randomized, open-label study to assess the efficacy, safety, and tolerability of dabrafenib administered as a single agent and in combination with trametinib in stage IV disease to subjects with BRAF mutant advanced non-small cell lung cancer. Subjects will receive dabrafenib 150 mg twice daily (BID) in monotherapy treatment and dabrafenib 150 mg bid and trametinib 2 mg once daily in combination therapy and continue on treatment until disease progression, death, or unacceptable adverse event.

Upstate Institutional Review Board (IRB) Number:

461053

Study Phase:

II

Patient Age Group:

Adults

Principal Investigator:

Stephen L Graziano, MD

ClinicalTrials.Gov ID:

NCT01336634

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Linda L Spillett, CCRP
Phone: 315-464-8237
Email: spilletl@upstate.edu

Return to Previous Page || Search Again